Rethinking R&D to balance efficiency, innovation and sustainability

In an era of skyrocketing research costs and complex drug delivery challenges, pharma industry leaders share their insights on adopting advanced technologies, data-driven decision-making, and sustainable practices to optimise R&D and drive impactful therapies to market

- 

Optimising R&D budgets for pharma companies involves a multi-pronged approach to balance efficiency with innovation

Optimising R&D budgets for pharma companies in today's high-cost, high-risk environment involves a multi-pronged approach to balance efficiency with innovation. Here are key strategies that can be adopted to maximise innovation and deliver impactful therapy.

Optimise portfolio management

● Pipeline optimisation: Conduct regular reviews ofthe R&D pipeline to identify underperforming projects and reallocate resources to higher-potential programs. This flexibility en-sures that R&D budgets are always directed toward projects with the best risk-reward ratio.

● Adaptive trial designs: Use adaptive trials that allow modifications in response to interim results. This can optimise both cost and development time.

Focus on high-value therapeutic areas

● Strategic prioritisation: Target diseases with high unmet needs where competition is lower, but demand is high, like certain cancers, neurological disorders, or rare diseases, Orphan drug indications etc. This focus can also yield higher pricing power and a favourable reimbursement landscape.

● Repurpose existing compounds: Repurposing compounds with known safety profiles for new indications re-duces time and cost in the early development stages, enabling faster entry into clinical trials with lower risk.

Adopt data-driven decision making

● Advanced analytics: Use of predictive analytics and machine learning to identify high-potential compounds and forecast trial outcomes.

● Real-world evidence (RWE): Utilisation of RWE from existing patient data to inform drug development decisions and identify unmet needs, reducing trial costs and duration.